Cytomegalovirus (CMV) disease is a major cause of morbidity and mortality after hematopoietic stem cell transplantation. Despite preemptive therapy, the incidence of early and late CMV disease remains as high as 15% in stem cell transplant patients 1 and late CMV reactivation occurs in 18% of CMV-seropositive recipients who discontinue preemptive therapy for CMV. 2 The most common presentation of CMV disease in transplant patients is CMV-pneumonitis, followed by gastrointestinal CMV disease. 2 Also, reports of late CMV infections in unusual sites such as the central nervous system and eyes are being increasingly recognized. 3, 4 CMV-induced hemorrhagic cystitis (HC) in transplant patients is uncommon. To our knowledge, in the literature there is only one reported case of CMV-induced HC in a patient after allogeneic bone marrow transplantation (BMT). 5 In this report, we describe a patient who developed CMV-induced HC 15 days after a matched unrelated donor peripheral blood stem cell transplantation (MUD PBSCT). To our best knowledge, this is the first report of CMV-induced HC after peripheral blood stem cell transplantation.
The patient was a 46-year-old male with a history of chronic myelogenous leukemia (CML) for 3 years. He was initially treated with hydroxyurea, alpha interferon and Ara-C with good response. He was in remission for 2 years. He was then noted to have an increasing leukocytosis. A bone marrow (BM) biopsy was consistent with accelerated phase of CML based on an increased number of blasts. He was started on Imatinib Mesylate. One month later, he was in morphological remission, but cytogenetic analysis was still positive for the Philadelphia chromosome. Subsequently, a MUD PBSCT was performed following standard conditioning with Busulfan (1 mg/kg q6h, 16 doses) and Cytoxan (60 mg/kg/day for 2 days). Both the patient and donor were CMV seropositive. GVHD prophylaxis-included ATG (2.5 mg/kg for 4 days), Methotrexate (5 mg/m 2 at 1st, 3rd, 6th and 11th days) and Tacrolimus (targeted at approximately 10 ng/ml).
The patient was admitted on the 19th post transplant day for evaluation of 5-days painless, gross hematuria. Laboratory tests showed hemoglobin of 7.4 g/dl and a platelet count of 15 000/ml. He was hydrated vigorously and transfused with platelets and red blood cells as needed. The bladder biopsy revealed chronic inflammation, granulation tissue with focal hemorrhage, and nuclear viral inclusions in stromal and endothelial cells consistent with CMV-cystitis ( Figure 1a) . Immunohistochemical analysis for CMV on the biopsy confirmed this diagnosis (Figure 1b) . Immunohistochemistry for BK virus was negative. He was initially treated with gancyclovir and broad-spectrum antibiotics. After 2 weeks of treatment, he was found to have increasing CMV titers and was switched to foscarnet. His CMV titers then stabilized and started to fall. He was discharged on maintenance therapy with foscarnet, 3 weeks after admission. On day 83 post transplant, the patient was readmitted with bilateral interstitial pneumonitis. The dose of foscarnet was increased. In addition, he was empirically treated for pneumocystis pneumonia with high-dose IV trimethoprim sulfamethoxazole and with broad-spectrum antibiotics. Bronchoalveolar lavage and a transbronchial lung biopsy were not diagnostic. He then became hypoxic and underwent open lung biopsy, which showed bronchiolitis obliterans organizing HC is usually caused by chemotherapy and can be seen in up to 70% of BM transplant patients following high-dose cyclophosphamide therapy. 6 Cyclophosphamide-induced HC typically occurs within 48 h of transplantation and is thought to be due to a direct toxic effect of a primary metabolite of cyclophosphamide on the bladder epithelium.
Other chemotherapeutic agents such as busulfan and radiation therapy have also been reported to cause HC. 7 Late onset HC after transplantation is usually attributed to viral infections. Polyomavirus (BK and JC virus) in particular, and less commonly adenovirus and herpes simplex virus can cause HC after hematopoietic transplantation. [8] [9] [10] CMV-induced HC should be recognized as another life-threatening complication of hematopoietic stem cell transplantation. Although rare, recognition and early diagnosis of this entity may reduce the mortality associated with CMV disease after stem cell transplantation. 
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